Virtual Advisory Boards VAB+

According to a recent study, 70% of life sciences companies indicate that their strategy to engage with KOLs is based on the position of the product in its lifecycle. 24% of surveyed companies engage with KOLs during pre-clinical phases of the product development and 41% begin developing relationships at phase III or after in the product life cycle. When engaging KOLs, a hybrid or virtual approach to management of KOLs is viewed as optimal for improved coordination and more consistent interactions.